The stock recorded a fall in short interest of -0.84% between ... The Company also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non …
SAN FRANCISCO, May 3— The wife of Genentech's chief executive officer is the focus of an insider trading investigation being conducted by the Securities and Exchange Commission, the company disclosed today. The investigation …
Roche won't "kill the hens that laid the golden eggs," Hunziker said. Genentech stock rose from around $84 to around $86 on news that Roche is indeed going ahead with its bid to acquire the company. The FT reports Roche is look at $95 a …
Since Roche announced its intention to buy the outstanding shares of Genentech, everbody’s been wondering whether the company’s top scientists will bolt. Genentech put a retention plan in place yesterday — but the main payouts would …
Genentech Inc.'s stock slipped 5.3% on Tuesday as investors winced at news that the U.S. attorney's office in Philadelphia was conducting an investigation into the marketing of the firm's top-selling drug, Rituxan. Shares in the …
April 20 (Reuters) - Genentech Inc. DNA.N said its board has approved the extension of its current stock repurchase program to up to an additional $2 billion shares for a total of $8 billion through June 30, 2008. The board maintained the …
Genentech, Inc. (NYSE:DNA) has announced that the biotech giant has authorized the extension of its current stock repurchase program through June 30, 2009 and it amended the current repurchase program. It is increasing the …
“If we don’t keep this drug [in stock], people will die,” Langston said ... whether they’re approved or designated. In contrast, drugmaker Genentech sent letters to rural hospitals on Jan. 1 listing dozens of drugs that would not qualify for ...
Update | 5:51 p.m. Shares of Genentech climbed on Monday afternoon following reports that the biotechnology company was close to a deal to be acquired by Roche Holding for $95 a share. Genentech’s shares rose for a time above …